Journals / Turkish Journal of Veterinary and Animal Sciences / 2003 / Cilt: 27 - Sayı: 2

Ritodrin ile $Ca^{++}$ kanla blokerlerinin tokolitik etkilerinin serum estradiol ve progesteron düzeyleri üzerinden karşılaştırılması

Comparison of the tocolytic effects of ritodrine and $Ca^{++}$ Channel blockers on serum oestradiol and progesterone levels

Pages
417–423
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Findings in the high-risk pregnancy group (hypertensive), to which no tocolytic agent was given, showed that the normal pregnancy period had not been completed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Experimental pregnancy was induced with gonadal steroids in in vivo ovariectomized rats.
📊
Key Findings & Data:In order to avoid early delivery, a betamimetic ritodrine and the Ca" channel blockers nitrendipine and nicardipine were administered to three separate groups.
💡
Conclusion & Impact:Findings in the high-risk pregnancy group (hypertensive), to which no tocolytic agent was given, showed that the normal pregnancy period had not been completed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Experimental pregnancy was induced with gonadal steroids in in vivo ovariectomized rats. Conditions for premature delivery were established by giving a salt-rich diet and administering oxytocin to induce high-risk pregnancy. In order to avoid early delivery, a betamimetic ritodrine and the Ca" channel blockers nitrendipine and nicardipine were administered to three separate groups. The effects of these three tocolytic agents were examined by determining serum oestradiol and progesterone levels. Additionally, systolic blood pressure was measured and tachycardia was observed.After the administration of tocolytic agents, it was observed that serum oestradiol levels were increased while there was a decrease in serum progesterone levels. These three drugs cause no difference in hormone levels and can be used as tocolytic agents; however, it was observed that ritodrine carries the risk of tachycardia. Findings in the high-risk pregnancy group (hypertensive), to which no tocolytic agent was given, showed that the normal pregnancy period had not been completed.

Özet

Bu çalışmada in vivo ovariektomi yapılan sıçanlara gonodal steroid uygulanarak deneysel gebelik oluşturuldu. Tuz diyeti ve oksitosin uygulanarak riskli gebelik tablosu oluşturmak suretiyle erken doğum ortamı hazırlandı. Erken doğumu önlemek için bir beta-mimetik olan ritodrin, Ca" kanal blokerleri olan nitrendipin ve nikardipin üç ayrı gruba verildi. Bu üç tokolitik ajanın etkileri serum estradiol ve progesteron düzeyleri tayin edilerek incelendi. Ayrıca sistolik basınç ve taşikardi de değerlendirildi.Tokolitik ilaç kullanan her üç grupta da estradiol düzeylerinde artış, progesteron düzeylerinde düşüş saptandı. Bu üç ilacın tokolitik etkili olarak kullanılabileceği, fakat ritodrinin taşikardi riski taşıdığı gözlendi. Tokolitik ajan verilmemiş riskli gebelik grubunda (hipertansif) saptanan bulgular bu grupta normal gebelik süresinin tamamlanmadığını gösterdi.

🔖

Cite This Article

TOSUN, F., GÖNENÇ, A., ŞİMŞEK, B. (2022). Ritodrin ile $Ca^{++}$ kanla blokerlerinin tokolitik etkilerinin serum estradiol ve progesteron düzeyleri üzerinden karşılaştırılması. Turkish Journal of Veterinary and Animal Sciences, Cilt: 27 - Sayı: 2, 417–423. https://ajindex.com/articles/615869

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Barden, T.P., Peter, J.B., Merkatz, R.I.: Ritodrine hydrocloride: A betamimetic agent for use in preterm labor. J. Am. Col. Obstet. Gynecoi. 1980; 56: 1-6.
  2. Rail, W.T.: Oxytocin, prostaglandins, ergot alkaloids and other drugs. Tocolytic agents. The pharmacological basis of therapeutics. Singapore, Gilman A.G., 1991; Vol. II. Chap. 39: 949-951.
  3. Kayaalp, S.O.: Beta-mimetik ilaçlar. Rasyonel tedavi yönünden tıbbi farmakoloji. Feryal matbacılık, Ankara, 1993; Cilt 3, Vol. 6.: 2374-2375.
  4. Brown, O.M.: Adrenergic drugs test book of pharmacology. W.B. Saunders Company, U.S.A. Smith M.C., 1992; Chap. 14: 157- 167. Wesselius-de-Casparis, A., Thiery, M., Yolesian, A., Baumgarten, K., Brosse, I., Gamisans, 0., Stolk, G.J., Vivier, W.: Results of double-blind, multicentre study with ritodrine in premature labour. Br. Med. J. 1971; 3: 144-147.
  5. Wilson, L, Michael, Jr., Parsons, T., Ouano, L, Flouret, G.: A new tocolytic agent: Development of an oxytocin antagonist for inhibiting uterine contractions. Am. J. Obstet. Gynecoi. 1990; 463: 195-202.
  6. Abel, H.M., Hollingsworth, M.: The potencies and selectivities of four calcium antagonists as inhibitors of uterine contractions in the rat in vivo. Br. J. Pharmac. 1985; 85: 263-269.
  7. Granger, E.S. Hollingsworth, M., Weston, A.H.: A comparison of several calcium antagonists on uterine, vascular and cardiac muscles from the rat. Br. J. Pharmac. 1985; 85: 255-262.
  8. Calixto, J.B.: Effect of diphenylhydantoin on drug and calcium induced contractions of isolated, rat uterus. A comparative study with nifedipine. Gen. Pharmac. 1987; 18: 237-243.
  9. Harden, T.K., Agonist-induced desensitization of the (3-adrenergic receptor-linked adenylate cyclase. Pharmac. Rev. 1983; 35: 5-35.
  10. Coruzz, G., Poll, E., Montanari, C, Bertaccini, G.: Pharmacological characterization of mare uterus motility with special reference to calcium antagonists and beta 2-adrenergic stimulants. Gen. Pharmac. 1989; 20: 513-518.
  11. Papatsonis. D.N.M., Van Geijn, H.P., Ader, H.J., Lange, F.M., Bleker, O.P., Dekker, G.A.: Nifedipine and ritodrine in the management of preterm labor: A randomized multicenter trial. Obstet. Gynecoi. 1997; 90: 230-234.
  12. Al-Najashi, S.S., Al-Mulhim, A.A.: Prolongation of pregnancy in multiple pregnancy. Int. J. Gynecoi. Obstet. 1996; 54: 131-135.
  13. Gyetvai, K., Hannah, M.E., Hodnett, E.D., Ohlsson, A.: Tocolytics for preterm labor: A systematic review. Obstet. Gynecoi. 1999; 94: 869-877.
  14. Ruzycky, A.L, Crankshaw, D.J., Triggle, D.J.: Ca++ channel ligancl